Pushing China to the forefront: When a first-in-China regulatory strategy makes sense

As reforms in China shorten clinical and regulatory timelines for biotechs across the board, the country has a growing chance to become the first stop for regulatory approvals of first-in-class drugs.

The decision to do so will primarily be informed by patient prevalence and market access, according to six company executives who spoke with BioCentury...